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1. INTRODUCTION {#myc12852-sec-0005}
===============

The epidemiology of yeast infections and fungemia continues to evolve throughout the world, in parallel with advances in medical care for critically ill and immunocompromised patients and the extensive use of antifungal agents.[1](#myc12852-bib-0001){ref-type="ref"}, [2](#myc12852-bib-0002){ref-type="ref"}, [3](#myc12852-bib-0003){ref-type="ref"}, [4](#myc12852-bib-0004){ref-type="ref"}, [5](#myc12852-bib-0005){ref-type="ref"} Among human fungal pathogens, *Candida* species are the most common yeast that cause bloodstream infections. In the majority of guidelines, echinocandins are the recommended first‐line therapy for candidemia, due to their clinical efficacy, fungicidal activity, favourable safety profile, and limited drug interactions, and concerns about fluconazole resistance.[6](#myc12852-bib-0006){ref-type="ref"}, [7](#myc12852-bib-0007){ref-type="ref"}, [8](#myc12852-bib-0008){ref-type="ref"}, [9](#myc12852-bib-0009){ref-type="ref"}, [10](#myc12852-bib-0010){ref-type="ref"}, [11](#myc12852-bib-0011){ref-type="ref"}

Among non‐*Candida* yeast, *Cryptococcus* is the most common fungal pathogen that causes community‐acquired invasive fungal disease and is intrinsically resistant to echinocandins.[4](#myc12852-bib-0004){ref-type="ref"}, [12](#myc12852-bib-0012){ref-type="ref"}, [13](#myc12852-bib-0013){ref-type="ref"} In Taiwan, the proportion of *Cryptococcus neoformans* from blood or bone marrow increased from 14% (8/59) between 1957 and 1972 to 33% (29/87) between 1982 and 1997.[14](#myc12852-bib-0014){ref-type="ref"} In addition, the emergence of rare yeast species such as *Trichosporon* and *Rhodotorula* poses a major threat because of their low susceptibility and potential to develop resistance to one or more antifungal agents.[4](#myc12852-bib-0004){ref-type="ref"}, [12](#myc12852-bib-0012){ref-type="ref"}, [13](#myc12852-bib-0013){ref-type="ref"}, [15](#myc12852-bib-0015){ref-type="ref"} Overall, common human yeast pathogens known to be intrinsically resistant or non‐susceptible to echinocandins (echinocandin non‐susceptible yeast, ENSY), including *Cryptococcus, Geotrichum, Malassezia, Pseudozyma, Rhodotorula, Saprochaete, Sporobolomyces* and *Trichosporon*.[4](#myc12852-bib-0004){ref-type="ref"}, [12](#myc12852-bib-0012){ref-type="ref"}, [15](#myc12852-bib-0015){ref-type="ref"}, [16](#myc12852-bib-0016){ref-type="ref"}, [17](#myc12852-bib-0017){ref-type="ref"}

Species identification is therefore important in order to target echinocandin therapy only at patients with susceptible yeast infections. However, it usually takes an additional 1‐3 days to identify yeast to species level using either manual methods or commercially available API ID32C, AuxaColor and Vitek 2 systems.[18](#myc12852-bib-0018){ref-type="ref"}, [19](#myc12852-bib-0019){ref-type="ref"} This delay in identification means that, in some cases, inappropriate echinocandin therapy may be initiated in patients with reported yeast isolation from blood. This underlines the limits of presumptive treatment for fungemia and stresses the necessity to introduce rapid identification methods for yeast species identification.[19](#myc12852-bib-0019){ref-type="ref"}

However, it is concerning that in a recent survey of mycology laboratory practice across seven Asian countries, rapid identification methods such as matrix‐assisted laser desorption ionisation‐time of flight mass spectrometry, and molecular identification methods such as PCR and sequencing were available only in 27 laboratories (12.3%) and 37 (16.9%) among 219 respondents, respectively.[20](#myc12852-bib-0020){ref-type="ref"} Most laboratories that perform identification with MALDI still require a subculture, which delays identification by 1 to 3 days (especially for slower growing basidiomycetous yeast). The potential impact of presumptive treatment with echinocandins for fungemia remains uncertain.

The aim of the current collaborative study was to determine the frequency of isolation from blood of yeast species that are intrinsically resistant or non‐susceptible to echinocandins. The study was based on laboratory‐based surveillance at 25 hospitals located in six Asian countries/regions.[21](#myc12852-bib-0021){ref-type="ref"} We also reviewed and compared published data around the world.

2. MATERIALS AND METHODS {#myc12852-sec-0006}
========================

2.1. Study design and mycology data collection {#myc12852-sec-0007}
----------------------------------------------

This was a 1‐year, cross‐sectional, laboratory‐based surveillance study conducted between July 1, 2010 and June 30, 2011. It was designed by the Asia Fungal Working Group (AFWG) under the auspices of the International Society for Human and Animal Mycology. A total of 25 hospitals participated in the study, located in China (10 hospitals), Hong Kong (1), India (4), Singapore (1), Taiwan (6) and Thailand (3). Details of the background of these hospitals, the capacity and practice of their mycology laboratories, and the incidence and distribution of candidemia have been published elsewhere.[21](#myc12852-bib-0021){ref-type="ref"} The study was approved by the Institutional Review Board or Research Ethics Committee at 21 of the hospitals; approval for research was waived at the other four centres.

Fungi were identified by the local microbiology or mycology laboratories at each study site. Blood culture systems and methods for fungal identification were as previously described.[21](#myc12852-bib-0021){ref-type="ref"} Microbiology laboratories in the participating hospitals identify the yeast by morphology (17 of 25 hospitals), CHROMagar (15), API20C of ID32C (17), manual assimilation/fermentation tests (6) and automatic methods (such as Vitek) (12). Only four hospitals provided the molecular identification methods such as PCR and sequencing in routine practice during the study period.

The data recorded for each isolate included the date of collection, hospital service, genus and species, whenever available. Duplicates were removed from the analysis. Yeast isolates were considered to be duplicate if they came from the same source type in the same patient, within 7 days of each other, and the final identifications were the same.[22](#myc12852-bib-0022){ref-type="ref"} The frequencies of ENSY among non‐duplicate yeast isolated from blood cultures were analysed; these included *Cryptococcus, Geotrichum, Malassezia, Pseudozyma, Rhodotorula, Saprochaete, Sporobolomyces* and *Trichosporon*.[4](#myc12852-bib-0004){ref-type="ref"}, [12](#myc12852-bib-0012){ref-type="ref"}, [15](#myc12852-bib-0015){ref-type="ref"}, [16](#myc12852-bib-0016){ref-type="ref"}, [17](#myc12852-bib-0017){ref-type="ref"}

2.2. Statistical analysis {#myc12852-sec-0008}
-------------------------

Statistical analyses were performed using SPSS v19 (SPSS Inc., Chicago, IL, USA). Categorical variables were analysed using the chi‐square test, and continuous variables were compared by Student\'s *t*‐test. A *P‐*value \< 0.05 was considered to be statistically significant.

3. RESULTS {#myc12852-sec-0009}
==========

3.1. Fungal isolates {#myc12852-sec-0010}
--------------------

From 51 254 clinical isolates submitted across the 25 participating hospitals, 2155 non‐duplicate yeast isolates from blood, and bone marrow specimens were included in the present analysis. Of these, 1980 (91.9%) isolates were *Candida* species and 175 (8.1%) were other, non‐*Candida* yeast (Table [1](#myc12852-tbl-0001){ref-type="table"}). Among the 175 non‐*Candida* yeast isolates, the majority were ENSY (146/175, 83.4%) which included *Cryptococcus* (109)*, Trichosporon* (23)*, Rhodotorula* (10) and *Malassezia* (4). In this study cohort, there were no *Geotrichum, Pseudozyma, Saprochaete* or *Sporobolomyces* which are intrinsically resistant to echinocandins.

###### 

Distribution of non‐duplicate yeast isolates in blood or bone marrow specimens

  Fungus                                                                                                      Number of isolates   (%)
  ----------------------------------------------------------------------------------------------------------- -------------------- ------
  Total yeast isolates                                                                                        2155                 100
  *Candida* species                                                                                           1980                 91.9
  Non‐*Candida* spp.                                                                                          175                  8.1
  *Cryptococcus* species[a](#myc12852-note-0003){ref-type="fn"} ^,^ [b](#myc12852-note-0004){ref-type="fn"}   109                  5.1
  *Trichosporon* species[a](#myc12852-note-0003){ref-type="fn"} ^,^ [c](#myc12852-note-0005){ref-type="fn"}   23                   1.1
  *Rhodotorula* species[a](#myc12852-note-0003){ref-type="fn"}                                                10                   0.5
  *Kodamaea (Pichia) ohmeri* [d](#myc12852-note-0006){ref-type="fn"}                                          7                    0.3
  *Malassezia* species[a](#myc12852-note-0003){ref-type="fn"} ^,^ [d](#myc12852-note-0006){ref-type="fn"}     4                    0.2
  *Hansenula anomala* (*Pichia anomala*)[d](#myc12852-note-0006){ref-type="fn"}                               4                    0.2
  *Hansenula polymorpha* [d](#myc12852-note-0006){ref-type="fn"}                                              2                    0.1
  *Yarrowia lipolytica* [d](#myc12852-note-0006){ref-type="fn"}                                               2                    0.1
  Other non‐*Candida* yeast[e](#myc12852-note-0007){ref-type="fn"}                                            14                   0.6

Yeast that are intrinsically resistant or with high probability of non‐susceptibility to echinocandins and ESCMID, and ECMM support a recommendation against use of echinocandins.[12](#myc12852-bib-0012){ref-type="ref"}

*Cryptococcus neoformans* (102 isolates), *Cryptococcus laurentii* (2) and *Cryptococcus* spp. (5).

*Trichosporon asahii* accounted for 9 of these isolates.

*Kodamaea* (*Pichia*) *ohmeri* (7 isolates; 4 from Taiwan and 3 from China)*, Hansenula anomala* (*Pichia anomala*) (4 isolates; 2 from Taiwan and 2 from India), *Hansenula polymorpha* (2 isolates; both from China), *Malassezia* species (4 isolates; 2 from Taiwan, 1 from Hong Kong and 1 from Thailand), *Yarrowia lipolytica* (2 isolates; both from Taiwan).

Fourteen isolates were not reported to a genus level.
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3.2. Genus distribution by country/region {#myc12852-sec-0011}
-----------------------------------------

The proportions of ENSY among yeast‐in‐blood isolates (overall, 146/2155, 6.7%) from each country/region are shown in Figure [1](#myc12852-fig-0001){ref-type="fig"}. ENSY proportions in most country/region are below 10%, except for Thailand, which ENSY proportions \>20% were observed. The proportion of ENSY isolates in tropical countries/regions (India, Thailand and Singapore) is higher than that in non‐tropical countries/regions (China, Hong Kong and Taiwan) (8.6% \[51/593\] vs 6.1% \[95/1562\], *P *=* *0.038). However, the higher rate of *Cryptococcus* spp. in Thailand when compared with the rates in other countries is the main reason for the above‐mentioned difference because, after excluding *Cryptococcus* spp., no significant difference was observed (1.6% \[9/551\] vs 1.9% \[28/1495\], *P *=* *0.852).

![Distribution within each country/region of 146 yeast isolated from blood and bone marrow specimens that were intrinsically resistant or had a high probability of non‐susceptibility to echinocandins. HK, Hong Kong](MYC-62-112-g001){#myc12852-fig-0001}

*Cryptococcus* spp. were most frequently observed in Thailand (20.2% of 173 yeast‐in‐blood isolates) but were rare in India (0.6% of 341 isolates) (Figure [1](#myc12852-fig-0001){ref-type="fig"}). A total of 23 *Trichosporon* isolates were reported, of which 11 were from Taiwan and four were from China. Among 10 *Rhodotorula* isolates, eight were reported from Taiwan.

3.3. Species distribution according to medical services {#myc12852-sec-0012}
-------------------------------------------------------

Among the 2155 yeast‐in‐blood isolates included in this analysis, information on the type of medical service from which they came were available for 2144 isolates. Of the 11 isolates for which medical service information was not available, three were ENSY. Thus, 143 ENSY were analysed according to medical service.

Overall, almost two‐thirds (59.4%) of ENSY came from general wards other than haematology‐oncology units (Figure [2](#myc12852-fig-0002){ref-type="fig"}A). However, this was largely because most yeast isolates overall came from these wards. When analysed according to each different type of medical service, the proportion of total isolates that were ENSY varied substantially, ranging from 2.9% in haematology‐oncology wards to 25.0% in outpatient clinics (Figure [2](#myc12852-fig-0002){ref-type="fig"}B). The proportions of ENSY in outpatient clinics is higher than haematology‐oncology wards and intensive care units (ICUs) (25.0% \[5/20\] vs 2.9% \[6/206\], *P *=* *0.001; 25.0% \[5/20\] vs 4.8% \[23/482\], *P *=* *0.003). The proportions of ENSY in emergency rooms (ERs) are higher than haematology‐oncology wards and ICUs (17.8% \[24/135\] vs 2.9% \[6/206\], *P *=* *0.001; 17.8% \[24/135\] vs 4.8% \[23/482\], *P *=* *0.003).

![Proportion of the total number of 143 yeast isolated from blood and bone marrow specimens that were intrinsically resistant or had a high probability of non‐susceptibility to echinocandins coming from each hospital service (A). Distribution within each medical service of yeast that were intrinsically resistant or had a high probability of non‐susceptibility to echinocandins (B). "Other wards" included general wards other than those specialising in haematology‐oncology. ER, emergency rooms; Hema, haematology‐oncology ward; ICU, intensive care unit; OPD, outpatient clinic](MYC-62-112-g002){#myc12852-fig-0002}

*Cryptococcus* accounted for 87.5% (21/24) of non‐*Candida* species isolated from ERs and 80.0% (4/5) from outpatient clinics. The proportion of *Cryptococcus* among non‐*Candida* species in ERs was significantly higher than in ICUs (52.1% \[12/23\], *P *=* *0.008) and haematology‐oncology wards (33.3% \[2/6\], *P *=* *0.016).

3.4. Species distribution by season {#myc12852-sec-0013}
-----------------------------------

Based on the date provided, the season of collection could be assigned to each isolate. The proportion of ENSY varied from 4.2% in autumn to 8.2% in winter, but these differences were not statistically significant. The proportions of individual species (*Cryptococcus, Trichosporon* and *Rhodotorula*) also did not vary substantially according to season, which was either due to small sample sizes or variations between countries (Figure [S1](#myc12852-sup-0001){ref-type="supplementary-material"}).

4. DISCUSSION {#myc12852-sec-0014}
=============

In this 1‐year surveillance study conducted in 25 hospitals across Asia, yeast that were intrinsically resistant or non‐susceptible to echinocandins accounted for 6.7% of 2155 non‐duplicate isolates from the blood. The frequency varied from 2.9% in haematology‐oncology wards to 25.0% in outpatient clinics.

Most non‐*Candida* yeast are known to be resistant to echinocandins;[4](#myc12852-bib-0004){ref-type="ref"} and indeed, this study showed that 83.4% of such isolates were ENSY. Hence, it is clinically significant that non‐*Candida* yeast accounted for 8.1% of all yeast‐in‐blood isolates (Table [1](#myc12852-tbl-0001){ref-type="table"}). Moreover, proportions varied substantially between the six countries/regions included in the survey, with non‐*Candida* species making up 24.9% of isolates from Thailand but only 2.3% of those from India. This wide variation in the proportion of non‐*Candida* species accords with other reports from around the world (summarised in Table [2](#myc12852-tbl-0002){ref-type="table"}). Overall, frequencies were higher in tropical countries, such as Mexico, Brazil and Thailand.[23](#myc12852-bib-0023){ref-type="ref"}, [24](#myc12852-bib-0024){ref-type="ref"}, [25](#myc12852-bib-0025){ref-type="ref"} Our study also showed similar results. (Figure [2](#myc12852-fig-0002){ref-type="fig"})

###### 

The proportions of non‐*Candida* yeast in blood specimens by region/country or patient population[a](#myc12852-note-0008){ref-type="fn"}

  Region/country                 Setting/population                         Study period   Patients (inpatients, outpatients or both)   Number of yeast isolates      Proportion of non‐*Candida* yeast   Proportion of *Cryptococcus* spp. in non‐*Candida* yeast   Remark                                                                                                                                                                                     References
  ------------------------------ ------------------------------------------ -------------- -------------------------------------------- ----------------------------- ----------------------------------- ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------
  Global                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Artemis study                  Multinational, multicentre, general        1997‐2007      both                                         11 240, non‐*Candida* yeast                                       32.2%                                                      *Saccharomyces* (11.7%), *Trichosporon* (10.6%), and *Rhodotorula* (4.1%) were the leading three non‐*Candida* fungi.                                                                      [22](#myc12852-bib-0022){ref-type="ref"}
  Americas                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  US                             Single hospital                            1998‐2010      both                                         2984                          3.1%                                NA                                                         *Rhodotorula* spp. (21 isolates), *Saccharomyces* (8) and *Trichosporon* (8) were the leading three non‐*Candida* fungi.                                                                   [31](#myc12852-bib-0031){ref-type="ref"}
  Mexico                         Single hospital                            2005‐2014      both                                         91                            34.1%                               93.9%                                                      Underlying disease was HIV/AIDS in 63% of cases                                                                                                                                            [23](#myc12852-bib-0023){ref-type="ref"}
  Argentina                      Multicentre                                2007‐2008      inpatients                                   461                           8.9%                                78.0%                                                      *C. neoformans* was mainly associated with HIV/AIDS                                                                                                                                        [28](#myc12852-bib-0028){ref-type="ref"}
  Paediatric patients (\<15 y)                                                             177                                          3.4%                          0%                                  2 isolates (33.3%) were *Trichosporon* spp.                                                                                                                                                                                                           
  Brazil                         Single hospital                            1996‐2004      both                                         1195                          14.6%                               45.4%                                                      *Pichia anomala* (18.4%) and *Rhodotorula* spp (16.1%) were also common.                                                                                                                   [24](#myc12852-bib-0024){ref-type="ref"}
  Brazil                         Single hospital                            2001‐2003      both                                         229                           2.6%                                100%                                                                                                                                                                                                                                                  [25](#myc12852-bib-0025){ref-type="ref"}
  2011‐2013                      288                                        5.9%           100%                                                                                                                                                                                                                                                                                                                                                                 
  Europe                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Europe                         Multicentre, cancer patients               2005‐2009      both                                         279                           7.5%                                19.0%                                                      8 *Trichosporon* spp. (38.1%) were the most common isolates in non‐*Candida* yeast                                                                                                         [32](#myc12852-bib-0032){ref-type="ref"}
  Sweden                         Nationwide                                 2005‐2006      both                                         403                           1.0%                                0%                                                                                                                                                                                                                                                    [33](#myc12852-bib-0033){ref-type="ref"}
  Belgium                        Multicentre                                2005‐2006      both                                         412                           7.8%                                12.5%                                                      21 *Saccharomyces cerevisiae* (65.6%) were the most common isolates in non‐*Candida* yeast                                                                                                 [26](#myc12852-bib-0026){ref-type="ref"}
  Denmark                        Nationwide                                 2004‐2009      both                                         3982                          1.1%                                31.8%                                                      22 *S. cerevisiae* (50%) were the most common isolates in non‐*Candida* yeast                                                                                                              [27](#myc12852-bib-0027){ref-type="ref"}
  France                         Regional, Paris                            NA                                                          3668                          5.1%                                73.3%                                                      19 *Geotrichum* (10.1%) were the second common non‐*Candida* yeast                                                                                                                         [12](#myc12852-bib-0012){ref-type="ref"}
  Italy                          Single hospital                            2005‐2013      both                                         1250                          1.9%                                29.2%                                                      Non‐*Candida* yeast were dominated by *Rhodotorula* spp. (n = 9) and *C. neoformans*, which together accounted for 1.3% of all bloodstream isolates and 66.6% of all non‐*Candida* yeast   [34](#myc12852-bib-0034){ref-type="ref"}
  Portugal                       Multicentre                                2011‐2012      inpatients                                   240                           3.8%                                88.9%                                                      *C. neoformans* was the most common isolate in non‐*Candida* yeast                                                                                                                         [29](#myc12852-bib-0029){ref-type="ref"}
  Spain                          Multicentre                                2009‐2010      both                                         1374                          1.9%                                38.5%                                                      *C. neoformans* was the most common isolate in non‐*Candida* yeast                                                                                                                         [35](#myc12852-bib-0035){ref-type="ref"}
  Spain                          Multicentre paediatric patients (\<15 y)   2009‐2010      inpatients                                   203                           1.0%                                0%                                                         Only two isolates were non‐*Candida* yeast; one was *Trichosporon asahii*, the other was *Rhodotorula glutinis*                                                                            [36](#myc12852-bib-0036){ref-type="ref"}
  Spain                          Multicentre                                2010‐2011      both                                         781                           2.4%                                26.3%                                                      *C. neoformans* was the most common non‐*Candida* yeast isolate, followed by *Trichosporon asahii* (15.8%)                                                                                 [37](#myc12852-bib-0037){ref-type="ref"}
  Asia                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Asia                           25 hospitals                               2010‐2011      both                                         2071                          7.8%                                67.7%                                                                                                                                                                                                                                                 This study
  China                          10 hospitals                               2010‐2011      both                                         325                           9.8%                                68.8%                                                                                                                                                                                                                                                 This study
  China                          Single hospital                            2010‐2012      inpatients                                   141                           7.8%                                45.5%                                                      *C. neoformans* was the most common isolate in non‐*Candida* yeast                                                                                                                         [38](#myc12852-bib-0038){ref-type="ref"}
  China                          4 hospitals                                2012‐2013      both                                         137                           8.0%                                9%                                                         *Pichia* spp. were the most common isolates in non‐*Candida* yeast (45%)                                                                                                                   [39](#myc12852-bib-0039){ref-type="ref"}
  Hong Kong                      Single hospital                            2010‐2011      both                                         34                            11.8%                               50%                                                                                                                                                                                                                                                   This study
  India                          Single hospital, paediatric patients       2007           inpatients                                   102                           21%                                 0%                                                         *P. anomala* was the most common isolate (85.7%), followed by *Trichosporon asahii* (14.3%)                                                                                                [40](#myc12852-bib-0040){ref-type="ref"}
  India                          4 hospitals                                2010‐2011      inpatients                                   305                           2.6%                                25%                                                                                                                                                                                                                                                   This study
  Singapore                      Single hospital                            2010‐2011      inpatients                                   78                            7.7%                                83.3%                                                                                                                                                                                                                                                 This study
  Taiwan                         6 hospitals                                2010‐2011      both                                         1160                          6.2%                                59.7%                                                                                                                                                                                                                                                 This study
  Thailand                       3 hospitals                                2010‐2011      both                                         169                           23.1%                               89.7%                                                                                                                                                                                                                                                 This study

Pubmed search using the following phrase: (fungemia \[Title/Abstract\]) OR yeast in blood cultures \[Title/Abstract\])) AND ("2007/1/1"\[Date ‐ Publication\]: "2015/11/31"\[Date ‐ Publication\]), accessed on 30 November 2015, limited to English literature. The publications that were most representative of the country/region or the most up‐to‐date were selected when more than one was found.
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In the present study, *Cryptococcus* was the predominant ENSY species. *Cryptococcus* is the leading ENSY pathogen in many countries worldwide (Table [2](#myc12852-tbl-0002){ref-type="table"}), although there are exceptions. For example, in Belgium and Denmark, *Saccharomyces cerevisiae* were the predominant non‐*Candida* isolates.[26](#myc12852-bib-0026){ref-type="ref"}, [27](#myc12852-bib-0027){ref-type="ref"} Higher proportions of *Cryptococcus* in blood are closely related to human immunodeficiency diseases.[23](#myc12852-bib-0023){ref-type="ref"}, [28](#myc12852-bib-0028){ref-type="ref"}, [29](#myc12852-bib-0029){ref-type="ref"} The proportions of non‐*Candida* yeast varied from 1.0% to 34% in different countries, patient papulations and medical settings (Table [2](#myc12852-tbl-0002){ref-type="table"}). In our study, almost a quarter of non‐*Candida* yeast occurred in the outpatient clinics or ERs, which may explain the difference between hospital‐based studies and inpatient‐only studies (Table [2](#myc12852-tbl-0002){ref-type="table"}).

Not all yeast are susceptible to echinocandins.[4](#myc12852-bib-0004){ref-type="ref"}, [12](#myc12852-bib-0012){ref-type="ref"}, [13](#myc12852-bib-0013){ref-type="ref"}, [15](#myc12852-bib-0015){ref-type="ref"}, [17](#myc12852-bib-0017){ref-type="ref"} Furthermore, there are currently no guidelines or recommendations that explicitly describe how to select appropriate presumptive therapy for fungemia in regions where rapid identification systems are not available and non‐*Candida* yeast‐in‐blood is common. Physicians in these countries should be familiar with common presentations and risk factors associated with *Cryptococcus* and other non‐*Candida* infections (Table [S1](#myc12852-sup-0001){ref-type="supplementary-material"}). For example, in Asia, cryptococcemia may be a possibility in a cirrhotic patient presenting at an ER, with altered mental status and community‐acquired sepsis of unknown source. Rapid microbiological evidence can be obtained by examining spinal fluid with India ink and detecting antigens in serum. These additional clues and tests may help physicians to select the most appropriate antifungal agent.[12](#myc12852-bib-0012){ref-type="ref"}

This study has several limitations. First, this laboratory‐based surveillance study is limited by the overall lack of clinical, outcome, and epidemiologic data, and was unable to assess the impact among patients with ENSY fungemia treated with echinocandins. Second, although patient isolates were deduplicated if within 7 days, this study did not provide the numbers of patients with these 2155 yeast isolates represent. Third, we did not collect isolates for identification at a central reference laboratory. Among 175 non‐*Candida* isolates, fourteen isolates were not identified to a genus level. Therefore, we probably underestimated the frequency and impact of rare and emerging yeast.[4](#myc12852-bib-0004){ref-type="ref"}, [12](#myc12852-bib-0012){ref-type="ref"}, [16](#myc12852-bib-0016){ref-type="ref"} Forth, antifungal susceptibility testing for these ENSY were not performed during this surveillance; and hence, we are unable to comment on the emergence of resistance to echinocandins.

The main strength of this study is an Asian multicentre laboratory‐based data analysis that the frequency of isolation from the blood of yeast species that are ENSY. The ENSY identified in this study were mainly belonged to Basidiomycetes (*Cryptococcus, Trichosporon* and *Rhodotorula*), a group well known intrinsically resistant to echinocandins. On the other hand, the non‐*Candida* Ascomycetes (such as *Pichia, Hansenula* and *Saccharomyces*) were rarely identified. A recent large‐scale study involving 1698 yeast isolates showed that Basidiomycetes are less susceptible all antifungal drugs tested compared to Ascomycetes.[17](#myc12852-bib-0017){ref-type="ref"}

In conclusion, this study revealed that yeast that are intrinsically resistant or non‐susceptibility to echinocandins are not uncommonly isolated from blood cultures in representative countries in Asia. These data suggest that an operational algorithm for management of patients when yeast are detected in blood specimens is warranted in areas where non‐*Candida* yeast‐in‐blood is common and in hospitals that do not possess the latest diagnostic technology. Improved communication among physicians and laboratories, as well as the acquisition of modern, rapid laboratory equipment that can provide results to the species level (and/or in vitro susceptibilities) are needed to guide antifungal therapy for yeast isolated from blood cultures.[30](#myc12852-bib-0030){ref-type="ref"}
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